GNTA (genenta.com) חוב לטווח ארוך

Genenta Science S.p.A. (GNTA) is an Italian pioneer developing brain tumor treatments through stem cell modification. The company is advancing targeted interferon delivery using the patient's own immune cells via lentiviral technologies. The individual long-term debt metric stands at 0.01. Market price action on GURU.Markets confirms the transparency of the reporting and the high scientific standing of the issuer's European management.

For Genenta Science (GNTA), which utilizes a virtual R&D model with outsourced production, changes in the company's long-term debt reflect its ability to finance external CMO/CRO contracts without compromising solvency. This metric aggregates obligations with maturities exceeding one year, allowing investors to assess the balance between leveraging debt for a technological leap and the risk of systemic capital degradation.